HOME >> MEDICINE >> NEWS
Clevidipine during heart surgery improves blood pressure control

Researchers today reported that an investigational anti-hypertensive therapy may perform better in controlling blood pressure than standard treatments for patients undergoing heart surgery, during a presentation at the American College of Cardiologys 56th Annual Scientific Session. Another study found that measuring a certain peptide can help evaluate dyspnea (shortness of breath) as heart- or lung-related in the general population. ACC.07 is the premier cardiovascular medical meeting, bringing together specialists from around the world to further breakthroughs in cardiovascular medicine.

Blood Pressure Control With Clevidipine Compared With Nitroglycerin, Sodium Nitroprusside, or Nicardipine in the Treatment of Perioperative Hypertension: Results of the Three Randomized ECLIPSE Trials (Presentation Number: 415-8)

While nitroglycerin and sodium nitroprusside have been utilized effectively in patients undergoing cardiac surgery to control blood pressure, a new therapy called clevidipine may perform even better, according to researchers at Duke University School of Medicine. Three separate studies evaluated clevidipine, a novel third-generation intravenous (IV) dihydropyridine calcium channel blocker, to measure blood pressure control against standard alternative agents.

The studies, collectively known as ECLIPSE (Evaluation of CLevidipine In the Postoperative Treatment of Hypertension Assessing Safety Events), compared clevidipine to each of three standard therapies: nitroglycerin, nitroprusside or nicardipine. The studies assessed blood pressure control by calculating the magnitude and duration of episodes when patients blood pressure went above or below predetermined acceptable ranges, based on the area under the blood-pressure-monitoring curve (AUC) that was outside the upper or lower limits of the range during surgery and for 24 hours afterwards.

The first two ECLIPSE studies found that patients treated wi
'"/>

Contact: Leslie Humbel
lhumbel@spectrumscience.com
504-613-2418
American College of Cardiology
27-Mar-2007


Page: 1 2 3

Related medicine news :

1. Michigan-CDC study supports value of social restrictions during influenza pandemics
2. Are parking garages safe during hurricanes?
3. Smoking may interfere with alcoholics neurocognitive recovery during abstinence
4. Genetic variations may predispose some men to suicidal thoughts during treatment for depression
5. Study questions risks of anti-bleeding drug during heart surgery
6. Pfizer Onocology press briefing scheduled during ASCO 2007 Annual Meeting
7. UW study to clarify safety, effectiveness of hormone therapy during menopause
8. Eating apples and fish during pregnancy may protect against childhood asthma and allergies
9. Clinical guidelines for blood conservation during cardiac procedures developed
10. Aspirin use during pregnancy could reduce risk of pre-eclampsia
11. Will the healthcare workers go to work during disasters?

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... ... at Monmouth, was one of the first doctors in the area to perform ... new approach have been impressive: faster recovery, decreased immediate and long-term pain, and ...
(Date:8/31/2015)... ... ... Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and approved as an ... from Don Bosco Prep in 1990 and was Class Salutatorian. He earned Varsity letters ... senior year. He was inducted into the National Honor Society as a sophomore, was ...
(Date:8/31/2015)... ... 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors can ... that contains a mathematical formula for modifying an image. The LUT changes every pixel's color ... LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or newer. ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet the ... costs? , In a commentary for The American Journal of Managed Care ... “clinical efficacy,” which would bind parties together in agreements to intervene at the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of diseases of the central nervous system ... submission has passed review by the US Food and ... 1 clinical trial in patients with metastatic colon cancer ... 31 December 2015. Bionomics, CEO & Managing ...
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
Cached News: